Loading…
Stem Cell Therapeutic and Research Reauthorization Act of 2015
Legislative Progress
Introduced
June 18, 2015
Latest Action
December 18, 2015
Primary Sponsor
Christopher H. SmithRepublican(NJ)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
90pct
183d open
vs 6,526 other HR bills in the 114th — cohort avg 56d
(This measure has not been amended since it was reported to the Senate on December 3, 2015. The summary of that version is repeated here.) Stem Cell Therapeutic and Research Reauthorization Act of 2015 (Sec. 2) This bill amends the Public Health Service Act and the Stem Cell Therapeutic and Research Act of 2005 to revise and extend through FY2020 the C.W. Bill Young Cell Transplantation Program and the National Cord Blood Inventory program. (These programs help match patients in need of a transplant with unrelated bone marrow and cord blood donors.) The Department of Health and Human Services (HHS) must review the state of the science of using adult stem cells and birthing tissues to develop new therapies and consider the inclusion of new therapies in the C.W. Bill Young Cell Transplantation Program. (Sec. 3) Requirements for HHS contracts under the Stem Cell Therapeutic and Research Act of 2005 are revised. (Sec. 4) HHS must determine whether to include peripheral blood stem cells and umbilical cord blood in the definition of human organ.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (12)
Became Public Law No: 114-104.
Became Public Law No: 114-104.
Signed by President.
Signed by President.
Presented to President.
Presented to President.
Motion to reconsider laid on the table Agreed to without objection.
On motion that the House suspend the rules and agree to the Senate amendment Agreed to by the Yeas and Nays: (2/3 required): 421 - 0 (Roll no. 695). (text as House agreed to Senate amendment: CR H9333)
HouseResolving differences -- House actions: On motion that the House suspend the rules and agree to the Senate amendment Agreed to by the Yeas and Nays: (2/3 required): 421 - 0 (Roll no. 695).(text as House agreed to Senate amendment: CR H9333)
HouseAt the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the chair announced that further proceedings on the motion would be postponed.
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2019 · first_quarter · Health Issues
Reauthorization of the CW Bill Young Cell Transplantation Program and National Cord Blood Inventory (no legislation yet introduced); Implementation of H.R. 2820, Stem Cell Therapeutic and Research Reauthorization Act of 2015 (Pub. L. No. 114-104); regenerative medicine issues
Client expense: Not reported · Firm income: $69,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
2018 · fourth_quarter · Health Issues
Implementation of H.R. 2820, "Stem Cell Therapeutic and Research Reauthorization Act of 2015" (Pub. L. No. 114-104); Regenerative Medicine legislation; H.R.195 (Continuing Resolution (through February 8, 2018)); H.R.1301 (Continuing Resolution); H.R.1625 (Vehicle for Consolidated Appropriations Act 2018); H.R.6157, DOD appropriations
Client expense: Not reported · Firm income: $69,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
2018 · third_quarter · Health Issues
Implementation of H.R. 2820, "Stem Cell Therapeutic and Research Reauthorization Act of 2015" (Pub. L. No. 114-104); Regenerative Medicine legislation; H.R.195 (Continuing Resolution (through February 8, 2018)); H.R.1301 (Continuing Resolution); H.R.1625 (Vehicle for Consolidated Appropriations Act 2018); H.R.6157, DOD appropriations
Client expense: Not reported · Firm income: $69,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
2018 · second_quarter · Health Issues
Implementation of H.R. 2820, "Stem Cell Therapeutic and Research Reauthorization Act of 2015" (Pub. L. No. 114-104); Regenerative Medicine legislation; H.R.195 (Continuing Resolution (through February 8, 2018)); H.R.1301 (Continuing Resolution); H.R.1625 (Vehicle for Consolidated Appropriations Act 2018)
Client expense: Not reported · Firm income: $69,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
2018 · first_quarter · Health Issues
Implementation of H.R. 2820, "Stem Cell Therapeutic and Research Reauthorization Act of 2015" (Pub. L. No. 114-104); Regenerative Medicine legislation; H.R.195 (Continuing Resolution (through February 8, 2018)); H.R.1301 (Continuing Resolution); H.R.1625 (Vehicle for Consolidated Appropriations Act 2018)
Client expense: Not reported · Firm income: $69,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
DEBATE - The House proceeded with forty minutes of debate on the motion to suspend the rules and concur in the Senate amendment to H.R. 2820.
Mr. Pitts moved that the House suspend the rules and agree to the Senate amendment. (consideration: CR H9333-9335, H9339)
Message on Senate action sent to the House.
Passed Senate with an amendment by Unanimous Consent. (consideration: CR S8560; text as passed Senate: CR S8560)
Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.(consideration: CR S8560; text as passed Senate: CR S8560)
Placed on Senate Legislative Calendar under General Orders. Calendar No. 311.
Committee on Health, Education, Labor, and Pensions. Reported by Senator Alexander with an amendment in the nature of a substitute. Without written report.
Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Motion to reconsider laid on the table Agreed to without objection.
On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H5801)
Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by voice vote.(text: CR H5801)
DEBATE - The House proceeded with forty minutes of debate on H.R. 2820.
Considered under suspension of the rules. (consideration: CR H5801-5804)
Mr. Guthrie moved to suspend the rules and pass the bill.
Placed on the Union Calendar, Calendar No. 183.
Reported by the Committee on Energy and Commerce. H. Rept. 114-242.
Congress.gov source codes: 5000, H12200
Ordered to be Reported by Voice Vote.
Committee Consideration and Mark-up Session Held.
Forwarded by Subcommittee to Full Committee by Voice Vote .
Subcommittee Consideration and Mark-up Session Held.
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
| House |
| Reported by |
| September 8, 2015 |
| Energy and Commerce Committee | House | Markup by | July 29, 2015 |
| Energy and Commerce Committee | House | Referred to | June 18, 2015 |
| September 9, 2015 |
| Engrossed in House | September 8, 2015 |
| Reported in House | September 8, 2015 |
| Introduced in House | June 18, 2015 |
| Enrolled Bill | -- |
| Democratic |
| ME |
| Dan Newhouse | Republican | WA |
| David Loebsack | Democratic | IA |
| David W. Jolly | Republican | FL |
| Dennis A. Ross | Republican | FL |
| Doris O. Matsui | Democratic | CA |
| Gus M. Bilirakis | Republican | FL |
| Leonard Lance | Republican | NJ |
| Lou Barletta | Republican | PA |
| Michael C. Burgess | Republican | TX |
| Peter A. DeFazio | Democratic | OR |
| Peter J. Roskam | Republican | IL |
| Raúl M. Grijalva | Democratic | AZ |
| Renee L. Ellmers | Republican | NC |
| Richard Hudson | Republican | NC |
| Richard M. Nolan | Democratic | MN |
| Robert B. Aderholt | Republican | AL |
| Tim Huelskamp | Republican | KS |
| Tim Murphy | Republican | PA |
2017 · fourth_quarter · Health Issues
Implementation of H.R. 2820, "Stem Cell Therapeutic and Research Reauthorization Act of 2015" (Pub. L. No. 114-104); Regenerative Medicine legislation
Client expense: Not reported · Firm income: $69,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
2017 · third_quarter · Health Issues
Implementation of H.R. 2820, "Stem Cell Therapeutic and Research Reauthorization Act of 2015" (Pub. L. No. 114-104).
Client expense: Not reported · Firm income: $69,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
2017 · second_quarter · Health Issues
Implementation of H.R. 2820, "Stem Cell Therapeutic and Research Reauthorization Act of 2015" (Pub. L. No. 114-104).
Client expense: Not reported · Firm income: $69,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
2017 · first_quarter · Health Issues
Implementation of H.R. 2820, "Stem Cell Therapeutic and Research Reauthorization Act of 2015" (Pub. L. No. 114-104).
Client expense: Not reported · Firm income: $69,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
2016 · fourth_quarter · Medical/Disease Research/Clinical Labs
Legislative and Federal agency activities related to H.R.2820 (Health Equity Act of 2013) and the Stem Cell Therapeutic and Research Reauthorization Act of 2015
Client expense: Not reported · Firm income: $10,000
Government targets: Food & Drug Administration (FDA), Health Resources & Services Administration (HRSA)
2016 · fourth_quarter · Health Issues
Legislative and Federal agency activities related to H.R.2820 (Health Equity Act of 2013) and the Stem Cell Therapeutic and Research Reauthorization Act of 2015
Client expense: Not reported · Firm income: $10,000
Government targets: Food & Drug Administration (FDA), Health Resources & Services Administration (HRSA)
2016 · fourth_quarter · Budget/Appropriations
Legislative and Federal agency activities related to H.R.2820 (Health Equity Act of 2013) and the Stem Cell Therapeutic and Research Reauthorization Act of 2015
Client expense: Not reported · Firm income: $10,000
Government targets: Food & Drug Administration (FDA), Health Resources & Services Administration (HRSA)
2016 · third_quarter · Medical/Disease Research/Clinical Labs
Legislative and Federal agency activities related to H.R.2820 (Health Equity Act of 2013) and the Stem Cell Therapeutic and Research Reauthorization Act of 2015
Client expense: Not reported · Firm income: $10,000
Government targets: Food & Drug Administration (FDA), Health Resources & Services Administration (HRSA)
2016 · third_quarter · Health Issues
Legislative and Federal agency activities related to H.R.2820 (Health Equity Act of 2013) and the Stem Cell Therapeutic and Research Reauthorization Act of 2015
Client expense: Not reported · Firm income: $10,000
Government targets: Food & Drug Administration (FDA), Health Resources & Services Administration (HRSA)
2016 · third_quarter · Budget/Appropriations
Legislative and Federal agency activities related to H.R.2820 (Health Equity Act of 2013) and the Stem Cell Therapeutic and Research Reauthorization Act of 2015
Client expense: Not reported · Firm income: $10,000
Government targets: Food & Drug Administration (FDA), Health Resources & Services Administration (HRSA)
2016 · second_quarter · Medical/Disease Research/Clinical Labs
Legislative and Federal agency activities related to H.R.2820 (Health Equity Act of 2013) and the Stem Cell Therapeutic and Research Reauthorization Act of 2015
Client expense: Not reported · Firm income: $30,000
Government targets: Food & Drug Administration (FDA), Health Resources & Services Administration (HRSA)
2016 · second_quarter · Health Issues
Legislative and Federal agency activities related to H.R.2820 (Health Equity Act of 2013) and the Stem Cell Therapeutic and Research Reauthorization Act of 2015
Client expense: Not reported · Firm income: $30,000
Government targets: Food & Drug Administration (FDA), Health Resources & Services Administration (HRSA)
2016 · second_quarter · Budget/Appropriations
Legislative and Federal agency activities related to H.R.2820 (Health Equity Act of 2013) and the Stem Cell Therapeutic and Research Reauthorization Act of 2015
Client expense: Not reported · Firm income: $30,000
Government targets: Food & Drug Administration (FDA), Health Resources & Services Administration (HRSA)
2016 · second_quarter · Health Issues
S 318, HR 531 Accelerating Biomedical Research Act HR 744, S 320 Medical Innovation Act (Swear Jar bill) HR 777 Permanent Investment in Health Research Act HR 6 21st Century Cures S 289, HR 2104 American Cures Act HR 2101 Research for All Act S 1077 Advancing Breakthrough Devices for Patients HR 2337 To amend the Federal Food, Drug, and Cosmetic Act to authorize priority review for breakthrough devices HR 160 Protect Medical Innovation Act of 2015 (to repeal the ACA medical device tax) S2014 HR3466 Next Generation Researchers Act HR 3171 HR 3215 HR 3429 S 1917 legislation relating to the regulation of fetal tissue research HR639 Improving Regulatory Transparency for New Medical Therapies Act (signed into law) HR 2820 Stem Cell Therapeutic and Research Reauthorization Act of 2015 (signed into law) HR 2646 S1945 Helping Families in Mental Health Crisis Act of 2015 HR 3731, S 2030 Rare Disease Fund Act of 2015 HR 3729 Limit Fetal Tissue Research S 2141 Transparent Ratings on Usability and Security to Transform Information Technology Act of 2015 or TRUST It Act (with respect to health information technology) S 2624 National Biomedical Research Act S 1878 Advancing Hope Act of 2015 S 2512 Adding Zika Virus to the FDA Priority Review Voucher Program Act S 1101 Medical Electronic Data Technology Enhancement for Consumers' Health Act S 1767 Combination Product Regulatory Fairness Act of 2015 S 1597 Patient-Focused Impact Assessment Act of 2015 S 2055 Medical Countermeasure Innovation Act of 2016 S 1945 Mental Health Reform Act of 2015 S 1622 FDA Device Accountability Act S 849 Advancing Research for Neurological Diseases Act of 2015 S 800 Enhancing the Stature and Visibility of Medical Rehabilitation Research at the NIH Act S 2700 FDA and NIH Workforce Authorities Modernization Act S 2713 Advancing Precision Medicine Act of 2016 S 2745 NIH Strategic Plan and Inclusion in Clinical Research S 2472 Promoting Biomedical Research and Public Health for Patients Act (to reduce regulatory burden on NIH-funded researchers)
Client expense: $15,681 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · first_quarter · Health Issues
S 318, HR 531 Accelerating Biomedical Research Act HR 744, S 320 Medical Innovation Act (Swear Jar bill) HR 777 Permanent Investment in Health Research Act HR 6 21st Century Cures S 289, HR 2104 American Cures Act HR 2101 Research for All Act S 1077 Advancing Breakthrough Devices for Patients HR 2337 To amend the Federal Food, Drug, and Cosmetic Act to authorize priority review for breakthrough devices HR 160 Protect Medical Innovation Act of 2015 (to repeal the ACA medical device tax) S2014 HR3466 Next Generation Researchers Act HR 3171 HR 3215 HR 3429 S 1917 legislation relating to the regulation of fetal tissue research HR639 Improving Regulatory Transparency for New Medical Therapies Act (signed into law) HR 2820 Stem Cell Therapeutic and Research Reauthorization Act of 2015 (signed into law) HR 2646 S1945 Helping Families in Mental Health Crisis Act of 2015 HR 3731, S 2030 Rare Disease Fund Act of 2015 HR 3729 Limit Fetal Tissue Research S 2141 Transparent Ratings on Usability and Security to Transform Information Technology Act of 2015 or TRUST It Act (with respect to health information technology) S 2624 National Biomedical Research Act S 1878 Advancing Hope Act of 2015 S 2512 Adding Zika Virus to the FDA Priority Review Voucher Program Act S 1101 Medical Electronic Data Technology Enhancement for Consumers' Health Act S 1767 Combination Product Regulatory Fairness Act of 2015 S 1597 Patient-Focused Impact Assessment Act of 2015 S 2055 Medical Countermeasure Innovation Act of 2016 S 1945 Mental Health Reform Act of 2015 S 1622 FDA Device Accountability Act S 849 Advancing Research for Neurological Diseases Act of 2015 S 800 Enhancing the Stature and Visibility of Medical Rehabilitation Research at the NIH Act S 2700 FDA and NIH Workforce Authorities Modernization Act S 2713 Advancing Precision Medicine Act of 2016 S 2745 NIH Strategic Plan and Inclusion in Clinical Research S 2472 Promoting Biomedical Research and Public Health for Patients Act (to reduce regulatory burden on NIH-funded researchers)
Client expense: $36,139 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · first_quarter · Budget/Appropriations
Legislative and Federal agency activities related to H.R.2820 (Health Equity Act of 2013) and the Stem Cell Therapeutic and Research Reauthorization Act of 2015
Client expense: Not reported · Firm income: $30,000
Government targets: Food & Drug Administration (FDA), Health Resources & Services Administration (HRSA)
2016 · first_quarter · Health Issues
Legislative and Federal agency activities related to H.R.2820 (Health Equity Act of 2013) and the Stem Cell Therapeutic and Research Reauthorization Act of 2015
Client expense: Not reported · Firm income: $30,000
Government targets: Food & Drug Administration (FDA), Health Resources & Services Administration (HRSA)
2016 · first_quarter · Medical/Disease Research/Clinical Labs
Legislative and Federal agency activities related to H.R.2820 (Health Equity Act of 2013) and the Stem Cell Therapeutic and Research Reauthorization Act of 2015
Client expense: Not reported · Firm income: $30,000
Government targets: Food & Drug Administration (FDA), Health Resources & Services Administration (HRSA)
2015 · third_quarter · Health Issues
Implementation of health care reform generally pertaining to pediactric health care and autism services Medicaid program reforms H.R. 546 and S. 298 (ACE Kids Act of 2015), all provisions Section 340B Drug Pricing Program ICD-10 Codes Implementation Program H.R. 2652(Protecting Patients and Physicians Against Coding Act of 2015). all provisions H.R. 2126 (Cutting Costlly Codes Act of 2015), All provisions H.R. 6 (21st Century Cures Act), all provisions Childhood Cancer STAR Act (draft bill) regarding cancer research, all provisions H.R. 3018(Code-FLEX Act of 2015), all provisions H.R. 2515 (Anna Westin Act of 2015), all provisions Regulations Regarding liver transplantation allocation methods H.R. 2820 (Stem cell therapeutic and research reauthorization Act of 2015), all provisions US Preventative Services Task Force draft recommendation on autism screening Sickle Cell Awareness Cardiomyopathy Awareness
Client expense: $113,664 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · fourth_quarter · Health Issues
blood safety issues; Stem Cell Therapeutic and Research Reauthorization Act of 2015, HR 2820; 21st Century Cures Act, HR 6
Client expense: Not reported · Firm income: Not reported
2015 · fourth_quarter · Medical/Disease Research/Clinical Labs
Food and Drug administration regulation of blood products, devices and cellular therapies 21st Century Cures Act, HR 6; Stem Cell Therapeutic and Research Reauthorization Act of 2015, HR 2820
Client expense: Not reported · Firm income: Not reported
2015 · fourth_quarter · Health Issues
S. 122: Safe and Affordable Drugs from Canada Act of 2015 - Provisions related to importation S. 185: Promise for Antibiotics and Therapeutics for Health (PATH) Act - Provisions related to antibiotic drug approval for a limited population S. 289: American Cures Act - Provisions related to NIH funding S. 320: Medical Innovation Act of 2015 - Provisions related to National Institutes of Health (NIH) funding and covered manufacturer supplemental fees S. 481: Improving Regulatory Transparency for New Medical Therapies Act - Provisions related to Drug Enforcement Administration (DEA) scheduling S. 483: Ensuring Patient Access and Effective Drug Enforcement Act of 2015 - Provisions related to registration under the Controlled Substances Act (CSA) S. 683: Compassionate Access, Research Expansion, and Respect States Act of 2015 - Provisions related to regulation of marijuana and impact on legitimate medical research S. 1128: Preserving Access to Orphan Drugs Act - Provisions related to orphan drug tax (113th Congress) S. 1790: Safe and Affordable Prescription Drugs Act of 2015 - Provisions related to importation S. 1767: The Combination Product Regulatory Fairness Act of 2015 - Provisions related to improvements in the regulation of combination drug-device products S. 2023: Prescription Drug Affordability Act of 2015 - Provisions related to importation S. 2055 - the Medical Countermeasure Innovation Act of 2015 H.R. 6: 21st Century Cures Act - Provisions related to biopharmaceutical discovery, development, delivery and transparency H.R. 471: Ensuring Patient Access and Effective Drug Enforcement Act of 2015 - Provisions related to registration under the CSA H.R. 639: Improving Regulatory Transparency for New Medical Therapies Act - Provisions related to DEA scheduling H.R. 880: American Research and Competitiveness Act of 2015 - Provisions related to the research and development (R&D) tax credit H.R. 909: Andrea Sloan Compassionate Use Reform and Enhancement Act - Provisions related to expanded access H.R. 1321: Microbead-Free Waters Act of 2015 - Provisions related to bills applicability to prescription drugs H.R. 1455: Speeding Access to Already Approved Pharmaceuticals Act of 2015 - Provisions requiring FDA to expedite review of pharmaceuticals that are approved for marketing in the European Union H.R. 1537: Advancing Hope Act of 2015 - Provisions related to the pediatric rare disease voucher program H.R. 1538: Compassionate Access, Research Expansion, and Respect States Act of 2015 - Provisions related to regulation of marijuana and impact on legitimate medical research H.R. 1576: Generic Complex Drugs Safety and Effectiveness for Patients Act of 2015 - Provisions related to the study of regulatory challenges for the approval of complex generic drugs H.R. 1635: Charlottes Web Medical Access Act of 2015 - Provisions related to regulation of marijuana and impact on legitimate medical research H.R. 2433: To amend the Federal Food, Drug, and Cosmetic Act with respect to enhancing combination products review - Provisions regarding the enhancement of combination products review H.R. 2479: To amend the Federal Food, Drug, and Cosmetic Act to provide for the issuance of up-to-date regulations and guidance applying to the dissemination by means of the Internet of information about medical products - Provisions related to dissemination of information about medical products H.R. 2536: Recovery Enhancement for Addiction Treatment Act - Provisions related to the treatment of drug addiction H.R. 2629: Antibiotic Development to Advance Patient Treatment Act - Provisions related to the approval of certain drugs for use in a limited population of patients H.R. 2805: Heroin and Prescription Opioid Abuse Prevention, Education, and Enforcement Act of 2015 - Provisions related to the treatment of heroin and prescription opioid abuse H.R. 2820: Stem Cell Therapeutic and Research Reauthorization Act of 2015 - Provisions related to the reauthorization of the National Cord Blood Inventory program and the C.W. Bill Young Cell Transplantation Program H.R. 2841: Fair Access for Safe and Timely Generics Act of 2015 - Provisions related to requiring innovator pharmaceutical manufacturers to provide samples of risk evaluation and mitigation strategy (REMS) covered products to generic manufacturers for bioequivalence testing H.R. 2872: Opioid Addiction Treatment Modernization Act - Provisions related to the treatment of opioid addiction H.R. 3014: Medical Controlled Substances Transportation Act of 2015 - Provisions related to the transport of controlled substances by physicians in certain situations HR. 3299 - the Strengthening Public Health Emergency Response Act of 2015 H.R. 3537: Synthetic Drug Control Act of 2015 - Provisions related to amending the Controlled Substances Analogue Act and the legislative scheduling of molecules used in legitimate medical research H.R. 3680: Co-Prescribing to Reduce Overdoses Act of 2015 - Provisions related to the prescribing of opioid overdose reversal drug to at-risk patients H.R. 3762, Restoring Americans Healthcare Freedom Reconciliation Act - Provisions related to amending and withdrawing funding from the Affordable Care Act The Regenerative Medicine Regulatory Improvement Act (discussion draft) - Provisions related to creating a new regulatory pathway to speed the approval of certain stem cell treatments Kids Count Act of 2015 (discussion draft) - Provisions for incentivizing pediatric rare disease drug development ADF Incentive Act of 2015 (discussion draft) - Provisions providing manufacturers an incentive to develop abuse deterrent formulations (ADF) of controlled substances Breakpoints (discussion draft) - Provisions relating to the updating of breakpoint information for antibiotics on an FDA managed website Drug Supply Chain Security Act issues including the Charitable Donation Exemption Discussion of Reforms to the Pediatric Research Equity Act (PREA) and Best Pharmaceuticals for Children Act (BPCA) Food and Drug Administration Safety and Innovation Act (FDASIA) policy issues Food and Drug Administration Proposed rule: Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products (78 Fed. Reg. 67985) - Provisions related to product labeling changes and related procedures Medicaid Managed Care, CHIP Delivered in Managed Care, Medicaid and CHIP Comprehensive Quality Strategies, and Revisions Related to Third Party Liability; Proposed Rules [CMS-2390-P] Provisions related to 340B program Senate HELP Committee innovation agenda - Provisions related to biopharmaceutical discovery and development and FDA policy Proposed HRSA 340B program mega-guidance - Provisions related to 340B program Implementation issues related to the Patient Protection and Affordable Care Act (PPACA) (Public Law 111-148), including health insurance exchanges Physician Payment Sunshine Act implementation issues, such as Open Payments System issues 340B Drug Discount Program policy issues General FDA advocacy Prescription Drug User Fee Act (PDUFA) negotiation and reauthorization Biopharmaceutical and medical innovation policy issues Drug development ecosystem policy issues Drug cost and pricing policy issues Transparency policy issues NIH Funding policy issues Precision Medicine Initiative Biomarker proposed legislation - Draft legislation related to developing a new approval pathway for biomarkers Rogue Internet Pharmacy policy issues Prescription drug abuse policy issues Drug compounding policy issues Nomination of Robert Califf to FDA Commissioner
Client expense: $380,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
2015 · fourth_quarter · Health Issues
H.R. 6, the 21st Century Cures Act; H.R. 2820, the Stem Cell Therapeutic and Research Reauthorization Act of 2015; S. 2822 Stem Cell Therapeutic and Research Reauthorization Act of 2015; general reauthorization of the C.W. Bill Young Cell Transplantation Program and the National Cord Blood Inventory
Client expense: Not reported · Firm income: $69,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE
2015 · fourth_quarter · Health Issues
HR 770 - To repeal the Patient Protection and Affordable Care Act and health care-related provisions in the Health Care and Education Reconciliation Act of 2010: entire bill HR 132/S 339 - ObamaCare Repeal Act: entire bill Public Law No. 111-148- Patient Protection and Affordable Care Act: entire law Public Law No. 111-152- Health Care and Education Reconciliation Act of 2010: entire law HR 2 - Medicare Access and CHIP Reauthorization Act SGR Repeal and Medicare Beneficiary Access Act: amendments and provisions related to and affecting reproductive health and family planning HR 1101 - Viral Hepatitis Testing Act: entire bill HR 1502 - Medicare Parity Act: entire bill S 737 - Ensuring Access to Primary Care for Women & Children Act: entire bill HR 117 - Reclaiming Individual Liberty Act: entire bill S 77 - Patient Choice Restoration Act: entire bill S 221 - Pregnancy Assistance Fund Expansion Act: entire bill HR 22 - Hire More Heroes Act: entire bill HR 1356/S 471 - Women Veterans Access to Quality Care Act: entire bill S 469 - Women Veterans and Families Health Services Act: entire bill HR 691 - Telehealth Modernization Act : entire bill HR 768 - Stop AIDS in Prison Act: entire bill HR 45 - Triple-Negative Breast Cancer Research and Education Act: entire bill HR 716/S 370 - Breast Density and Mammography Reporting Act: entire bill HR 1197 - Accelerating the End of Breast Cancer Act: entire bill S 697 - Frank R. Lautenberg Chemical Safety for the 21st Century Act: entire bill S 1016 - Preserving Freedom and Choice in Health Care Act: entire bill HR 2054 - To amend title 38, United States Code, to provide for increased access to Department of Veterans Affairs medical care for women veterans: entire bill HR 2300 - Empowering Patients First Act: entire bill S 1438 - Allowing Greater Access to Safe and Effective Contraception Act: entire bill S Res 193 - A resolution celebrating the 50th anniversary of the historic Griswold v. Connecticut decision of the Supreme Court of the United States and expressing the sense of the Senate that the case was an important step forward in helping ensure that all people of the United States are able to use contraceptives to plan pregnancies and have healthier babies.: entire resolution HR 2653 - American Health Care Reform Act: entire bill HR 3163/S 1532 - Affordability Is Access Act: entire bill HR 2866 - To amend title XXVII of the Public Health Service Act to provide for a special enrollment period for pregnant women, and for other purposes: entire bill HR 6 - 21st Century Cures Act: entire bill HR 2066 - Telehealth Enhancement Act: entire bill HR 1345 - Health IT Modernization for Underserved Communities Act: entire bill HR 270 - Flexibility in Health IT Reporting (Flex-IT) Act: entire bill HR 2646 - Helping Families in Mental Health Crisis Act: entire bill HR 2725 - 21st Century Care for Military and Veterans Act: entire bill HR 2355 - Women's Preventive Health Awareness Campaign: entire bill HR 2820 - Stem Cell Therapeutic and Research Reauthorization Act: entire bill HR 2866/S 2220 - the Healthy MOM Act S 1299/HR 938 - Garrett Lee Smith Memorial Act Reauthorization HR 3171 - To amend the Public Health Service Act to prohibit certain research on the transplantation of human fetal tissue obtained pursuant to an abortion. S 1919 - A bill to amend the Patient Protection and Affordable Care Act to protect rights of conscience with regard to requirements for coverage of specific items and services, to amend the Public Health Service Act to prohibit certain abortion-related discrimination in governmental activities, and for other purposes. HR 3443 - Women's Health Accountability Act HR 2972 - Equal Access to Abortion Coverage in Health Insurance (EACH Woman) Act HR 3498 - Human Cloning Prohibition Act S 1917 - A bill to prohibit the provision of Federal funds to an entity that receives compensation for facilitating the donation of fetal tissue derived from an abortion. H Res 558/S Res 327 - A resolution condemning violence that targets healthcare for women. Reducing Unexpected Deaths in Infants and Children Act of 2015
Client expense: $42,941 · Firm income: Not reported
Government targets: Administration for Children & Families (ACF), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), Peace Corps, SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), Veterans Affairs, Dept of (VA)
2015 · fourth_quarter · Health Issues
Legislative and Federal agency activities related to H.R.2820 (Health Equity Act of 2013) and the Stem Cell Therapeutic and Research Reauthorization Act of 2015
Client expense: Not reported · Firm income: $30,000
Government targets: Food & Drug Administration (FDA), Health Resources & Services Administration (HRSA)
2015 · fourth_quarter · Medical/Disease Research/Clinical Labs
Legislative and Federal agency activities related to H.R.2820 (Health Equity Act of 2013) and the Stem Cell Therapeutic and Research Reauthorization Act of 2015
Client expense: Not reported · Firm income: $30,000
Government targets: Food & Drug Administration (FDA), Health Resources & Services Administration (HRSA)
2015 · fourth_quarter · Budget/Appropriations
Legislative and Federal agency activities related to H.R.2820 (Health Equity Act of 2013) and the Stem Cell Therapeutic and Research Reauthorization Act of 2015
Client expense: Not reported · Firm income: $30,000
Government targets: Food & Drug Administration (FDA), Health Resources & Services Administration (HRSA)
2015 · fourth_quarter · Health Issues
S 318, HR 531 Accelerating Biomedical Research Act HR 744, S 320 Medical Innovation Act (Swear Jar bill) HR 777 Permanent Investment in Health Research Act HR 6 21st Century Cures S 289, HR 2104 American Cures Act HR 2101 Research for All Act S 1077 Advancing Breakthrough Devices for Patients HR 2337 To amend the Federal Food, Drug, and Cosmetic Act to authorize priority review for breakthrough devices HR 160 Protect Medical Innovation Act of 2015 (to repeal the ACA medical device tax) S2014 HR3466 Next Generation Researchers Act HR 3171 HR 3215 HR 3429 S 1917 legislation relating to the regulation of fetal tissue research HR639 Improving Regulatory Transparency for New Medical Therapies Act (signed into law) HR 2820 Stem Cell Therapeutic and Research Reauthorization Act of 2015 (signed into law) HR 2646 S1945 Helping Families in Mental Health Crisis Act of 2015 HR 3731 Rare Disease Fund Act of 2015 (Andrew Los brainchild) HR 3729 Limit Fetal Tissue Research S 2141 Transparent Ratings on Usability and Security to Transform Information Technology Act of 2015 or TRUST It Act (with respect to health information technology)
Client expense: $58,549 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · fourth_quarter · Health Issues
S. 122: Safe and Affordable Drugs from Canada Act of 2015 - Provisions related to importation S. 185: Promise for Antibiotics and Therapeutics for Health (PATH) Act - Provisions related to antibiotic drug approval for a limited population S. 289: American Cures Act - Provisions related to National Institutes of Health (NIH) funding S. 320: Medical Innovation Act of 2015 - Provisions related to NIH funding and covered manufacturer supplemental fees S. 481: Improving Regulatory Transparency for New Medical Therapies Act - Provisions related to Drug Enforcement Administration (DEA) scheduling S. 483: Ensuring Patient Access and Effective Drug Enforcement Act of 2015 - Provisions related to registration under the Controlled Substances Act (CSA) S. 683: Compassionate Access, Research Expansion, and Respect States (CARERS) Act of 2015 - Provisions related to regulation of marijuana and impact on legitimate medical research S. 1128: Preserving Access to Orphan Drugs Act - Provisions related to orphan drug tax (113th Congress) S. 1790: Safe and Affordable Prescription Drugs Act of 2015 - Provisions related to importation S. 1767: Combination Product Regulatory Fairness Act of 2015 - Provisions related to improvements in the regulation of combination drug-device products S. 2023: Prescription Drug Affordability Act of 2015 - Provisions related to importation H.R. 6: 21st Century Cures Act - Provisions related to biopharmaceutical discovery, development, delivery and transparency H.R. 471: Ensuring Patient Access and Effective Drug Enforcement Act of 2015 - Provisions related to registration under the CSA H.R. 639: Improving Regulatory Transparency for New Medical Therapies Act - Provisions related to DEA scheduling H.R. 880: American Research and Competitiveness Act of 2015 - Provisions related to the research and development (R&D) tax credit H.R. 909: Andrea Sloan Compassionate Use Reform and Enhancement Act - Provisions related to expanded access H.R. 1321: Microbead-Free Waters Act of 2015 - Provisions related to bills applicability to prescription drugs H.R. 1455: Speeding Access to Already Approved Pharmaceuticals Act of 2015 - Provisions requiring FDA to expedite review of pharmaceuticals that are approved for marketing in the European Union H.R. 1537: Advancing Hope Act of 2015 - Provisions related to the pediatric rare disease voucher program H.R. 1538: Compassionate Access, Research Expansion, and Respect States (CARERS) Act of 2015 - Provisions related to regulation of marijuana and impact on legitimate medical research H.R. 1576: Generic Complex Drugs Safety and Effectiveness for Patients Act of 2015 - Provisions related to the study of regulatory challenges for the approval of complex generic drugs H.R. 1635: Charlottes Web Medical Access Act of 2015 - Provisions related to regulation of marijuana and impact on legitimate medical research H.R. 2433: To amend the Federal Food, Drug, and Cosmetic Act with respect to enhancing combination products review - Provisions regarding the enhancement of combination products review H.R. 2479: To amend the Federal Food, Drug, and Cosmetic Act to provide for the issuance of up-to-date regulations and guidance applying to the dissemination by means of the Internet of information about medical products - Provisions related to dissemination of information about medical products H.R. 2536: Recovery Enhancement for Addiction Treatment Act - Provisions related to the treatment of drug addiction H.R. 2629: Antibiotic Development to Advance Patient Treatment Act - Provisions related to the approval of certain drugs for use in a limited population of patients H.R. 2805: Heroin and Prescription Opioid Abuse Prevention, Education, and Enforcement Act of 2015 - Provisions related to the treatment of heroin and prescription opioid abuse H.R. 2820: Stem Cell Therapeutic and Research Reauthorization Act of 2015 - Provisions related to the reauthorization of the National Cord Blood Inventory program and the C.W. Bill Young Cell Transplantation Program H.R. 2841: Fair Access for Safe and Timely Generics Act of 2015 - Provisions related to requiring innovator pharmaceutical manufacturers to provide samples of risk evaluation and mitigation strategy (REMS) covered products to generic manufacturers for bioequivalence testing H.R. 2872: Opioid Addiction Treatment Modernization Act - Provisions related to the treatment of opioid addiction H.R. 3014: Medical Controlled Substances Transportation Act of 2015 - Provisions related to the transport of controlled substances by physicians in certain situations H.R. 3537: Synthetic Drug Control Act of 2015 - Provisions related to amending the Controlled Substances Analogue Act and the legislative scheduling of molecules used in legitimate medical research H.R. 3680: Co-Prescribing to Reduce Overdoses Act of 2015 - Provisions related to the prescribing of opioid overdose reversal drug to at-risk patients H.R. 3762, Restoring Americans Healthcare Freedom Reconciliation Act of 2015 - Provisions related to amending and withdrawing funding from the Affordable Care Act The Regenerative Medicine Regulatory Improvement Act (discussion draft) - Provisions related to creating a new regulatory pathway to speed the approval of certain stem cell treatments Kids Count Act of 2015 (discussion draft) - Provisions for incentivizing pediatric rare disease drug development ADF Incentive Act of 2015 (discussion draft) - Provisions providing manufacturers an incentive to develop abuse deterrent formulations (ADF) of controlled substances Breakpoints (discussion draft) - Provisions relating to the updating of breakpoint information for antibiotics on an FDA managed website Drug Supply Chain Security Act issues including the Charitable Donation Exemption Discussion of Reforms to the Pediatric Research Equity Act (PREA) and Best Pharmaceuticals for Children Act (BPCA) Food and Drug Administration Safety and Innovation Act (FDASIA) policy issues Food and Drug Administration Proposed rule: Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products (78 Fed. Reg. 67985) - Provisions related to product labeling changes and related procedures Medicaid Managed Care, CHIP Delivered in Managed Care, Medicaid and CHIP Comprehensive Quality Strategies, and Revisions Related to Third Party Liability; Proposed rules [CMS-2390-P] - Provisions related to 340B program Senate HELP Committee innovation agenda - Provisions related to biopharmaceutical discovery and development and FDA policy Proposed HRSA 340B program mega-guidance - Provisions related to 340B program Implementation issues related to the Patient Protection and Affordable Care Act (PPACA) (Public Law 111-148), including health insurance exchanges Physician Payment Sunshine Act implementation issues, such as Open Payments System issues 340B Drug Discount Program policy issues General FDA advocacy Prescription Drug User Fee Act (PDUFA) negotiation and reauthorization Biopharmaceutical and medical innovation policy issues Drug development ecosystem policy issues Drug cost and pricing policy issues Transparency policy issues NIH Funding policy issues Precision Medicine Initiative Biomarker proposed legislation - Draft legislation related to developing a new approval pathway for biomarkers Rogue Internet Pharmacy policy issues Prescription drug abuse policy issues Drug compounding policy issues Nomination of Robert Califf to FDA Commissioner
Client expense: $3,820,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)
2015 · fourth_quarter · Health Issues
H.R.3020/S.1695, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2016, Donor recruitment and transplant services Congressional Caucus to Cure Blood Cancers and Other Blood Disorders, generally H.R.2820, Stem Cell Therapeutic and Research Reauthorization Act of 2015, Donor recruitment and transplant services H.R.2029, Continuing Appropriations Act, FY2016, Donor recruitment and transplant services
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · third_quarter · Health Issues
blood safety issues; Stem Cell Therapeutic and Research Reauthorization Act of 2015, HR 2820; 21st Century Cures Act, HR 6
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · third_quarter · Medical/Disease Research/Clinical Labs
Food and Drug administration regulation of blood products, devices and cellular therapies 21st Century Cures Act, HR 6; Stem Cell Therapeutic and Research Reauthorization Act of 2015, HR 2820
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · third_quarter · Health Issues
HR 770 - To repeal the Patient Protection and Affordable Care Act and health care-related provisions in the Health Care and Education Reconciliation Act of 2010: entire bill HR 132/S 339 - ObamaCare Repeal Act: entire bill Public Law No. 111-148- Patient Protection and Affordable Care Act: entire law Public Law No. 111-152- Health Care and Education Reconciliation Act of 2010: entire law HR 2 - Medicare Access and CHIP Reauthorization Act SGR Repeal and Medicare Beneficiary Access Act: amendments and provisions related to and affecting reproductive health and family planning HR 1101 - Viral Hepatitis Testing Act: entire bill HR 1502 - Medicare Parity Act: entire bill S 737 - Ensuring Access to Primary Care for Women & Children Act: entire bill HR 117 - Reclaiming Individual Liberty Act: entire bill S 77 - Patient Choice Restoration Act: entire bill S 221 - Pregnancy Assistance Fund Expansion Act: entire bill HR 22 - Hire More Heroes Act: entire bill HR 1356/S 471 - Women Veterans Access to Quality Care Act: entire bill S 469 - Women Veterans and Families Health Services Act: entire bill HR 691 - Telehealth Modernization Act : entire bill HR 768 - Stop AIDS in Prison Act: entire bill HR 45 - Triple-Negative Breast Cancer Research and Education Act: entire bill HR 716/S 370 - Breast Density and Mammography Reporting Act: entire bill HR 1197 - Accelerating the End of Breast Cancer Act: entire bill S 697 - Frank R. Lautenberg Chemical Safety for the 21st Century Act: entire bill S 1016 - Preserving Freedom and Choice in Health Care Act: entire bill HR 2054 - To amend title 38, United States Code, to provide for increased access to Department of Veterans Affairs medical care for women veterans: entire bill HR 2300 - Empowering Patients First Act: entire bill S 1438 - Allowing Greater Access to Safe and Effective Contraception Act: entire bill S Res 193 - A resolution celebrating the 50th anniversary of the historic Griswold v. Connecticut decision of the Supreme Court of the United States and expressing the sense of the Senate that the case was an important step forward in helping ensure that all people of the United States are able to use contraceptives to plan pregnancies and have healthier babies.: entire resolution HR 2653 - American Health Care Reform Act: entire bill HR 3163/S 1532 - Affordability Is Access Act: entire bill HR 2866 - To amend title XXVII of the Public Health Service Act to provide for a special enrollment period for pregnant women, and for other purposes: entire bill HR 6 - 21st Century Cures Act: entire bill HR 2066 - Telehealth Enhancement Act: entire bill HR 1345 - Health IT Modernization for Underserved Communities Act: entire bill HR 270 - Flexibility in Health IT Reporting (Flex-IT) Act: entire bill HR 2646 - Helping Families in Mental Health Crisis Act: entire bill HR 2725 - 21st Century Care for Military and Veterans Act: entire bill HR 2355 - Women's Preventive Health Awareness Campaign: entire bill HR 2820 - Stem Cell Therapeutic and Research Reauthorization Act: entire bill HR 2866 - the Healthy MOM Act S 1299/HR 938 - Garrett Lee Smith Memorial Act Reauthorization HR 3171 - To amend the Public Health Service Act to prohibit certain research on the transplantation of human fetal tissue obtained pursuant to an abortion. S 1919 - A bill to amend the Patient Protection and Affordable Care Act to protect rights of conscience with regard to requirements for coverage of specific items and services, to amend the Public Health Service Act to prohibit certain abortion-related discrimination in governmental activities, and for other purposes. HR 3443 - Women's Health Accountability Act HR 2972 - Equal Access to Abortion Coverage in Health Insurance (EACH Woman) Act HR 3498 - Human Cloning Prohibition Act S 1917 - A bill to prohibit the provision of Federal funds to an entity that receives compensation for facilitating the donation of fetal tissue derived from an abortion.
Client expense: $278,546 · Firm income: Not reported
Government targets: Administration for Children & Families (ACF), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), Peace Corps, SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), Veterans Affairs, Dept of (VA)
2015 · third_quarter · Health Issues
-Expressed support for federal rural health programs -Requested congressional letters of support for Specialized Programs of Research Excellence (SPOREs) grant at the National Institutes of Health -Discussed support of the 21st Century Cures Act (H.R.6) -Discussed Stem Cell Therapeutic and Research Act (H.R.2820) -Discussed potential changes to existing federal policy regarding biomedical research regulations -Discussed FDA regulation of regenerative medicine products -Expressed concerns regarding the NIH salary cap on extramural research
Client expense: $138,163 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · third_quarter · Health Issues
Implementation of health care reform generally pertaining to pediactric health care and autism services Medicaid program reforms H.R. 546 and S. 298 (ACE Kids Act of 2015), all provisions Section 340B Drug Pricing Program ICD-10 Codes Implementation Program H.R. 2652(Protecting Patients and Physicians Against Coding Act of 2015). all provisions H.R. 2126 (Cutting Costlly Codes Act of 2015), All provisions H.R. 6 (21st Century Cures Act), all provisions Childhood Cancer STAR Act (draft bill) regarding cancer research, all provisions H.R. 3018(Code-FLEX Act of 2015), all provisions H.R. 2515 (Anna Westin Act of 2015), all provisions Regulations Regarding liver transplantation allocation methods H.R. 2820 (Stem cell therapeutic and research reauthorization Act of 2015), all provisions US Preventative Services Task Force draft recommendation on autism screening Sickle Cell Awareness Cardiomyopathy Awareness
Client expense: $113,664 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · third_quarter · Health Issues
Implementation of health care reform generally pertaining to pediatric health care and autism services Medicaid program reforms H.R. 546 and S. 298 (ACE Kids Act of 2015), all provisions Section 340B Drug Pricing Program ICD-10 Codes Implementation Program H.R. 2652 (Protecting Patients and Physicians Against Coding Act of 2015), all provisions H.R. 2126 (Cutting Costly Codes Act of 2015), all provisions H.R. 6 (21st Century Cures Act), all provisions Childhood Cancer STAR Act (draft bill) regarding cancer research, all provisions H.R. 3018 (Code - FLEX Act of 2015), all provisions H.R. 2515 (Anna Westin Act of 2015), all provisions Regulations regarding liver transplantation allocation methods H.R. 2820 (Stem Cell Therapeutic and Research Reauthorization Act of 2015), all provisions US Preventative Services Task Force draft recommendation on autism screening
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · third_quarter · Health Issues
Legislative and Federal agency activities related to H.R.2820 (Health Equity Act of 2013) and the Stem Cell Therapeutic and Research Reauthorization Act of 2015
Client expense: Not reported · Firm income: $30,000
Government targets: Food & Drug Administration (FDA), Health Resources & Services Administration (HRSA)
2015 · third_quarter · Budget/Appropriations
Legislative and Federal agency activities related to H.R.2820 (Health Equity Act of 2013) and the Stem Cell Therapeutic and Research Reauthorization Act of 2015
Client expense: Not reported · Firm income: $30,000
Government targets: Food & Drug Administration (FDA), Health Resources & Services Administration (HRSA)
2015 · third_quarter · Medical/Disease Research/Clinical Labs
Legislative and Federal agency activities related to H.R.2820 (Health Equity Act of 2013) and the Stem Cell Therapeutic and Research Reauthorization Act of 2015
Client expense: Not reported · Firm income: $30,000
Government targets: Food & Drug Administration (FDA), Health Resources & Services Administration (HRSA)
2015 · third_quarter · Health Issues
H.R. 6, the 21st Century Cures Act; H.R. 2820, the Stem Cell Therapeutic and Research Reauthorization Act of 2015; general reauthorization of the C.W. Bill Young Cell Transplantation Program and the National Cord Blood Inventory
Client expense: Not reported · Firm income: $65,750
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE
2015 · third_quarter · Health Issues
H.R.3020/S.1695, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2016, Donor recruitment and transplant services. Congressional Caucus to Cure Blood Cancers and Other Blood Disorders, generally. H.R.2820, Stem Cell Therapeutic and Research Reauthorization Act of 2015, Donor recruitment and transplant services.
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · second_quarter · Medical/Disease Research/Clinical Labs
Food and Drug administration regulation of blood products, devices and cellular therapies 21st Century Cures Act, HR 6; Stem Cell Therapeutic and Research Reauthorization Act of 2015, HR 2820
Client expense: Not reported · Firm income: Not reported
2015 · second_quarter · Health Issues
blood safety issues; Stem Cell Therapeutic and Research Reauthorization Act of 2015, HR 2820; 21st Century Cures Act, HR 6
Client expense: Not reported · Firm income: Not reported
2015 · second_quarter · Health Issues
HR 770 - To repeal the Patient Protection and Affordable Care Act and health care-related provisions in the Health Care and Education Reconciliation Act of 2010: entire bill HR 132/S 339 - ObamaCare Repeal Act: entire bill Public Law No. 111-148- Patient Protection and Affordable Care Act: entire law Public Law No. 111-152- Health Care and Education Reconciliation Act of 2010: entire law HR 2 - Medicare Access and CHIP Reauthorization Act SGR Repeal and Medicare Beneficiary Access Act: amendments and provisions related to and affecting reproductive health and family planning HR 1101 - Viral Hepatitis Testing Act: entire bill HR 1502 - Medicare Parity Act: entire bill S 737 - Ensuring Access to Primary Care for Women & Children Act: entire bill HR 117 - Reclaiming Individual Liberty Act: entire bill S 77 - Patient Choice Restoration Act: entire bill S 221 - Pregnancy Assistance Fund Expansion Act: entire bill HR 22 - Hire More Heroes Act: entire bill HR 1356/S 471 - Women Veterans Access to Quality Care Act: entire bill S 469 - Women Veterans and Families Health Services Act: entire bill HR 691 - Telehealth Modernization Act : entire bill HR 768 - Stop AIDS in Prison Act: entire bill HR 45 - Triple-Negative Breast Cancer Research and Education Act: entire bill HR 716/S 370 - Breast Density and Mammography Reporting Act: entire bill HR 1197 - Accelerating the End of Breast Cancer Act: entire bill S 697 - Frank R. Lautenberg Chemical Safety for the 21st Century Act: entire bill S 1016 - Preserving Freedom and Choice in Health Care Act: entire bill HR 2054 - To amend title 38, United States Code, to provide for increased access to Department of Veterans Affairs medical care for women veterans: entire bill HR 2300 - Empowering Patients First Act: entire bill S 1438 - Allowing Greater Access to Safe and Effective Contraception Act: entire bill S Res 193 - A resolution celebrating the 50th anniversary of the historic Griswold v. Connecticut decision of the Supreme Court of the United States and expressing the sense of the Senate that the case was an important step forward in helping ensure that all people of the United States are able to use contraceptives to plan pregnancies and have healthier babies.: entire resolution HR 2653 - American Health Care Reform Act: entire bill S 1532 - Affordability Is Access Act: entire bill HR 2866 - To amend title XXVII of the Public Health Service Act to provide for a special enrollment period for pregnant women, and for other purposes: entire bill HR 6 - 21st Century Cures Act: entire bill HR 2066 - Telehealth Enhancement Act: entire bill HR 1345 - Health IT Modernization for Underserved Communities Act: entire bill HR 270 - Flexibility in Health IT Reporting (Flex-IT) Act: entire bill HR 2646 - Helping Families in Mental Health Crisis Act: entire bill HR 2725 - 21st Century Care for Military and Veterans Act: entire bill HR 2355 - Women's Preventive Health Awareness Campaign: entire bill HR 2820 - Stem Cell Therapeutic and Research Reauthorization Act: entire bill S 1299/HR 938 - Garrett Lee Smith Memorial Act Reauthorization
Client expense: $172,805 · Firm income: Not reported
Government targets: Administration for Children & Families (ACF), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), Peace Corps, SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), Veterans Affairs, Dept of (VA)
2015 · second_quarter · Budget/Appropriations
Legislative and Federal agency activities related to H.R.2820 (Health Equity Act of 2013) and the Stem Cell Therapeutic and Research Reauthorization Act of 2015
Client expense: Not reported · Firm income: $10,000
Government targets: Food & Drug Administration (FDA), Health Resources & Services Administration (HRSA)